Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Virology|February 24, 2006
Parapoxviruses of seals and sea lions make up a distinct subclade within the genus ParapoxvirusHendrik H Nollens, Frances M D Gulland, Elliott R Jacobson, et al.Virology|October 27, 2015
Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutantJessica Tate, Rachel L Boldt, Baron D McFadden, et al.Diseases of Aquatic Organisms|May 27, 2006
Seroepidemiology of parapoxvirus infections in captive and free-ranging California sea lions Zalophus californianusHendrik H Nollens, Frances M D Gulland, Jorge A Hernandez, et al.Journal of Wildlife Diseases|May 16, 2006
Pathology and preliminary characterization of a parapoxvirus isolated from a California sea lion (Zalophus californianus)Hendrik H Nollens, Elliott R Jacobson, Frances M D Gulland, et al.Malaria Journal|May 5, 2018
Growth of Plasmodium falciparum in response to a rotating magnetic fieldRebecca C Gilson, Robert J Deissler, Richard F Bihary, et al.Journal of Virology|February 21, 2012
Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae)Priscila P Afonso, Patrícia M Silva, Laila C Schnellrath, et al.Vaccine|December 3, 2014
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessmentThomas P Monath, Stephen J Seligman, James S Robertson, et al.Virology|March 4, 2008
Marker rescue mapping of the combined Condit/Dales collection of temperature-sensitive vaccinia virus mutantsSayuri E M Kato, Nissin Moussatche, Susan M D'Costa, et al.Vaccine|October 20, 2020
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformAriane Volkmann, Anna-Lise Williamson, Heinz Weidenthaler, et al.Vaccine|September 10, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccinesRichard C Condit, Denny Kim, James S Robertson, et al.Pageof 10